ArticleMolecular biomedicine2025
High sensitivity detection of Hepatitis B virus RNA based on 3D-DNA nanomachine and protein nanopore sensing.
Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Serum Hepatitis B virus (HBV) RNA serves as a non-invasive biomarker for monitoring chronic hepatitis B and guiding treatment decisions. However, current diagnostic tests relying on Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) require centralized facilities and tedious operational steps, and there is currently no standardized HBV RNA detection method. Herein, we describe the rapid amplification-free detection of HBV RNA in clinical serum samples via a nanopore sensing method. Our method involves the design of a DNA nanomachine capable of translation of each target HBV RNA into a large amount of 7-nt single-strand DNA (ssDNA) as signal reporters that produce blockage features when passing through an alpha-hemolysin (α-HL) nanopore, the target can be quantified by identifying the frequency of this blockage occurrence. We demonstrate that this unique nanopore sensing feature not only distinguishes Signal Report (SR) DNA from interfering nucleic acids in clinical serum samples but also ensures a high assay sensitivity with a limit-of-detection (LOD) at 12.5 fM. The clinical potential of this method was validated through testing serum samples from 26 HBV-infected-patients and 7 healthy-participants. When compared with the RT-qPCR method, it showed only one false result, achieving an accuracy rate of 97.0%. Additionally, testing results for 18 cases during the treatment period demonstrated that our method's conclusions on continued treatment and drug discontinuation were highly consistent with clinical diagnoses, with an accuracy rate of 100%. Therefore, the method developed in this study expands the clinical applications of 3D DNA nanomachine and nanopore sensing technology in clinical detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.